Determined DNA sequences derived from a papillomavirus genome, their uses for in vitro diagnostic purposes and the production of antigenic compositions

• US 7,063,963 B2
• Filed: 10/22/2003
• Issued: 06/20/2006
• Est. Priority Date: 03/21/1986
• Status: Expired due to Fees

• Current Assignee: Roche Molecular Systems (Roche Holding AG)
• Original Assignee: Roche Molecular Systems (Roche Holding AG)
• Inventors: Cole, Stewart, Streeck, Rolf E.
• Primary Examiner(s): SALIMI, ALI REZA
• Application Number:
  US10/691,776
• Publication Number:
  US 20040132012A1
• Time in Patent Office: 972 Days
• Field of Search: 435/69.1, 435/6, 435/91.33, 536/23.72
• US Class Current: 435/69.1
• CPC Class Codes: A61K 39/00 Medicinal preparations containing antigens or antibodies materials for immunoassay G01N33/53
• CPC Class Codes: A61P 31/12 Antivirals
• CPC Class Codes: A61P 37/04 Immunostimulants
• CPC Class Codes: C07K 14/005 from viruses
• CPC Class Codes: C12N 2710/20022 New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
• CPC Class Codes: C12N 7/00 Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof preparing medicinal viral antigen or antibody compositions, e.g. virus vaccines, A61K39/00
• CPC Class Codes: C12Q 1/708 for papilloma

Abstract

The invention concerns DNA fragments derived from the genomic DNA of HPV-33. These fragments are selected from the group of fragments extending between the nucleotide extremities defined hereafter in relation to the nucleotide-numbering in FIGS. 1a and 1b respectively:

• • 76–556
  • 543–864
  • 867–2811
  • 2728–3808
  • 3326–3575
  • 3842–4079
  • 4198–5611
  • 5516–8091.

The invention also relates to the use of these fragments as probes for the detection of HPV in tissue cultures.

Claims

1. A method for detecting the presence of human papillomavirus in a sample comprising:

combining a test sample containing sample nucleic acids with a composition comprising at least one nucleotide sequence from human papillomavirus-33, wherein the human papillomavirus-33 is defined by the sequence as shown in FIG. 1a and FIG. 1b; and

identifying the presence of hybrids formed between said sample nucleic acids and said at least one nucleotide sequence from human papillomavirus-33.

2. The method according to claim 1, wherein the at least one nucleotide from human papillomavirus-33 is labeled.

3. The method according to claim 2, wherein the at least one nucleotide from human papillomavirus-33 is labeled with at least one of an enzyme, a radioactive compound, and a fluorescent compound.

4. The method according to claim 1, wherein the identifying the presence of hybrids is preformed enzymatically, radioactively, or fluorescently.

5. The method of claim 1, wherein the at least one nucleotide sequence from human papillomavirus-33 comprises the complete human papillomavirus-33 DNA sequence as shown in FIGS. 1a and 1b.

6. The method of claim 1, wherein the at least one nucleotide sequence from human papillomavirus-33 comprises at least one nucleotide sequence selected from the following group of nucleotide sequences numbered as shown in FIGS. 1a and 1b:

a) 76–

556, b) 543–

864, c) 867–

2811, d) 2728–

3808, e) 3326–

3575, f) 3842–

4079, g) 4198–

5611, and h) 5516–

7091.

7. The method of claim 6, wherein the at least one nucleotide sequence from human papillomavirus-33 comprises at least one nucleotide sequence selected from the following group of nucleotide sequences numbered as shown in FIGS. 1a and 1b:

a) 4198–

5611, and b) 5516–

7091.

8. The method of claim 1, wherein the at least one nucleotide sequence from human papillomavirus-33 comprises at least one nucleotide sequence selected from the following group of nucleotide sequences numbered as shown in FIGS. 1a and 1b:

a) 109–

556, b) 573–

864, c) 879–

2811, d) 2749–

3808, e) 3326–

3575, f) 3842–

4079, g) 4210–

5611 and h) 5594–

7091.

9. The method of claim 8, wherein the at least one nucleotide sequence from human papillomavirus-33 comprises at least one nucleotide sequence selected from the following group of nucleotide sequences numbered as shown in FIGS. 1a and 1b:

a) 4210–

5611 and b) 5594–

7091.

10. The method of claim 1, wherein the at least one nucleotide sequence from human papillomavirus-33 comprises a 78- base sequence identified as 78-1 in FIG. 3.

11. The method of claim 1, wherein the at least one nucleotide sequence from human papillomavirus-33 comprises a 156- base sequence identified as 78-1 and 78-2 in FIG. 3.

12. The method of claim 1, wherein the at least one nucleotide sequence from human papillomavirus-33 comprises a nucleotide sequence extending from nucleotide 229 to nucleotide 404 of FIG. 1a.